Your shopping cart is currently empty

Imgatuzumab (RG 7160; GA201) is a humanized, glycoengineered IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This product inhibits EGFR-mediated signaling (such as MAPK and PI3K pathways) by blocking EGF binding and inducing receptor internalization. As a glycoengineered antibody, Imgatuzumab features enhanced affinity for Fc gamma RIIIa, resulting in potent antibody-dependent cellular cytotoxicity (ADCC). It is used to research EGFR-overexpressing solid tumors and demonstrates synergistic effects when combined with chemotherapeutic agents.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $747 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $1,200 | 2-4 weeks | 2-4 weeks |
| Description | Imgatuzumab (RG 7160; GA201) is a humanized, glycoengineered IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This product inhibits EGFR-mediated signaling (such as MAPK and PI3K pathways) by blocking EGF binding and inducing receptor internalization. As a glycoengineered antibody, Imgatuzumab features enhanced affinity for Fc gamma RIIIa, resulting in potent antibody-dependent cellular cytotoxicity (ADCC). It is used to research EGFR-overexpressing solid tumors and demonstrates synergistic effects when combined with chemotherapeutic agents. |
| In vitro | Imgatuzumab specifically binds EGFR and exhibits potent ADCC activity in A549 and HCT116 cells. Co-treatment with Gemcitabine, Cisplatin, or Paclitaxel, or pretreatment with Dexamethasone, does not impair Imgatuzumab-mediated ADCC; instead, combination therapies enhance overall anti-tumor efficacy [1]. |
| In vivo | Imgatuzumab significantly inhibits tumor growth in lung and colorectal cancer xenograft mouse models. Combination with Gemcitabine or Paclitaxel leads to enhanced tumor regression and prolonged survival compared to monotherapy, demonstrating synergistic anti-tumor efficacy [1]. |
| Synonyms | RO 5083945, RG 7160, Anti-EGFR Recombinant Antibody |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | EGFR |
| Molecular Weight | 145.0 kDa |
| Cas No. | 959963-46-3 |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 2 years, 4°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.